Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Neurocrine Biosciences Inc (NASDAQ:NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.Sales reached $805.5 million, beating the consensus of $792.47 million.Fourth-quarter net product sales were $798.3 million, up 29% year over year.Ingrezza (drug for involuntary movements) fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion, reflecting 7% and 9% growth year-over-year, respectively.Results reflected double-dig ...